PharmaMar announces that its partner Taiho files NDA for Yondelis in Japan for soft-tissue sarcoma

(Pharmamar) The J-NDA is supported by a pivotal Phase 2 trial showing that in Japanese patients Yondelis (trabectedin) provided clinical benefit, resulting in a significantly superior median progression-free survival compared to best supportive care (5.6 versus 0.9 months). The NDA will receive priority review by regulatory agency and will seek approval for various subtypes of advanced soft-tissue sarcoma in Japan.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news